10724-1-AP

antibody from Proteintech Group

Targeting: NRAS N-ras

Provider product page for 10724-1-AP

Western blot

ELISA

Immunocytochemistry

Immunohistochemistry

Flow cytometry

Antibody data

Antibody Data
Antigen structure
References [42]
Comments [0]
Validations
Western blot [1]
Immunocytochemistry [1]
Immunohistochemistry [2]

Submit

Product number: 10724-1-AP - Provider product page
Provider: Proteintech Group
Proper citation: Proteintech Cat#10724-1-AP, RRID:AB_2154209
Product name: NRAS antibody
Antibody type: Polyclonal
Description: KD/KO validated NRAS antibody (Cat. #10724-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: FC, IF, IHC, WB, ELISA.
Reactivity: Human, Mouse, Rat
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

NRAS protein structure - 10724-1-AP shown in red.

Submitted references Manganese-tannic acid immunomodulators potentiate PDGFRβ CAR-T cell function for additive therapy against liver fibrosis.

Wang X, Duan J, Cai H, Liu C, Ding H, Xue Y, Yu S, Peng S, Feng Y, Qi J, Tang W, Yi F, Mu C, Zhao S, Zhu Q
Journal of controlled release : official journal of the Controlled Release Society 2026 Jun 10;394:114871

NRAS and SREBF1 identified as mitophagy-associated risk genes for rheumatoid arthritis through interpretable machine learning and experimental validation studies.

Li H, Liu P, Han X, Si S, Li Z, Zhao C, Zhao X, Zhou X, Liu M
BMC rheumatology 2026 Feb 7;10(1)

Characterizations of G-Quadruplex RNA-Protein Interactions in Living Cells.

Tang F, Liang X, Porter DF, Miao W, Maehlmann K, Yuan J, Khavari PA, Wang Y
Analytical chemistry 2026 Apr 28;98(16):12090-12098

Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.

Kamgar M, Hobbes GA, Davidson R, Dorbin D, Herrera J, Langenheim JF, Burge RA, Aldakkak M, Conrardy RD, Szabo A, Thalji SZ, Mayer B, Grahl JJ, Chung BY, Phan A, Thomas JP, Seo YD, Evans DB, Christians KK, Erickson B, Hall WA, George B, Tsai S, Lytle NK, Der CJ, Kurzrock R, McFall T
Cancer research 2026 Apr 15;86(8):2042-2059

Nuclear force transmission drives cancer-associated fibroblast activation under BRAF inhibition.

Wang J, Soley BDS, Xiao Y, Siegfried LG, Zhou L, Xu M, Millar SE, Andl T, Zhang Y
bioRxiv : the preprint server for biology 2025 Sep 9;

Albiflorin attenuates post-myocardial infarction cardiac fibrosis through inhibiting the RAS-ERK/MAPK signaling pathway.

Lv M, Yu Y, Niu H, Yu D
Biochemical and biophysical research communications 2025 Oct 1;783:152644

Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies.

Feichtenschlager V, Zheng YJ, Qu T, Hohlova D, Callanan C, Chen L, Chen C, Ho W, Lee A, Hwang Y, Courtright A, Nguyen T, Marsicovetere O, Muñoz DP, Rappersberger K, Coppe JP, Ortiz-Urda S
Communications medicine 2025 Jun 5;5(1):216

Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors.

Srivastava J, Yadav VK, Jimenez RV, Phadatare PR, Inamdar NA, Young MM, Bacchiocchi A, Halaban R, Fang B, Pulido AM, Tsai KY, Smalley KSM, Koomen JM, Rodriguez PC, Premi S
Cancer research 2025 Jun 16;85(12):2268-2287

The Function and Clinical Significance of TRPV2 in Human Colon Cancer.

Nakamichi N, Shiozaki A, Kosuga T, Shimizu H, Kudou M, Kiuchi J, Nanishi K, Arita T, Konishi H, Komatsu S, Kuriu Y, Kubota T, Fujiwara H, Morinaga Y, Konishi E, Otsuji E
Annals of surgical oncology 2025 Aug 19;

Design, synthesis, and evaluation of novel quindoline derivatives with fork-shaped side chains as RNA G-quadruplex stabilizers for repressing oncogene NRAS translation.

Sun JW, Zou J, Zheng Y, Yuan H, Xie YZ, Wang XN, Ou TM
European journal of medicinal chemistry 2024 May 5;271:116406

Dihydroartemisinin-driven selective anti-lung cancer proliferation by binding to EGFR and inhibition of NRAS signaling pathway-induced DNA damage.

Li LG, Peng XC, Yang ZY, Han N, Gou CL, Shi J, Yu LL, Chen NN, Yu TT, Li TF, Li XY, Hu J
Scientific reports 2024 May 22;14(1):11704

A pan-KRAS degrader for the treatment of KRAS-mutant cancers.

Yang J, Wang QL, Wang GN, Ye JC, Li ZQ, Wang JY, Liang ZH, Li SX, Sun C, Liao WT, Gao YJ, Wang J, Mao Y, Yu C, Feng GK, Zeng MS
Cell discovery 2024 Jun 28;10(1):70

A non-canonical role for a small nucleolar RNA in ribosome biogenesis and senescence.

Cheng Y, Wang S, Zhang H, Lee JS, Ni C, Guo J, Chen E, Wang S, Acharya A, Chang TC, Buszczak M, Zhu H, Mendell JT
Cell 2024 Aug 22;187(17):4770-4789.e23

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.

Pucci P, Lee LC, Han M, Matthews JD, Jahangiri L, Schlederer M, Manners E, Sorby-Adams A, Kaggie J, Trigg RM, Steel C, Hare L, James ER, Prokoph N, Ducray SP, Merkel O, Rifatbegovic F, Luo J, Taschner-Mandl S, Kenner L, Burke GAA, Turner SD
Nature communications 2024 Apr 23;15(1):3422

NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth.

Cai C, Tu J, Najarro J, Zhang R, Fan H, Zhang FQ, Li J, Xie Z, Su R, Dong L, Arellano N, Ciboddo M, Elf SE, Gao X, Chen J, Wu R
Molecular cancer research : MCR 2024 Apr 2;22(4):386-401

microRNA-203 functions as a natural Ras inhibitor in hepatocellular carcinoma.

Guo J, Li L, Deng N, Xu Y, Wang G, Luo H, Xu C, Li X
American journal of cancer research 2023;13(4):1295-1309

Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.

Chen PY, Huang BJ, Harris M, Boone C, Wang W, Carias H, Mesiona B, Mavrici D, Kohler AC, Bollag G, Zhang C, Zhang Y, Shannon K
JCI insight 2023 Sep 8;8(17)

Near-Infrared Phototheranostic Iron Pyrite Nanocrystals Simultaneously Induce Dual Cell Death Pathways via Enhanced Fenton Reactions in Triple-Negative Breast Cancer.

Zhao C, Liu Z, Chang CC, Chen YC, Zhang Q, Zhang XD, Andreou C, Pang J, Liu ZX, Wang DY, Kircher MF, Yang J
ACS nano 2023 Mar 14;17(5):4261-4278

A First-Class Degrader Candidate Targeting Both KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination.

Miyamoto-Sato E, Imanishi S, Huang L, Itakura S, Iwasaki Y, Ishizaka M
Molecules (Basel, Switzerland) 2023 Jul 24;28(14)

Unveiling the role of G-quadruplex structure in promoter region: Regulation of ABCA1 expression in macrophages possibly via NONO protein recruitment.

Xiao CD, Jia MH, Zhong MQ, Xu Y, Yu ZT, He ZY, Lu X, Zhang Y, Zhou X, Fu LY, Shen XC
International journal of biological macromolecules 2023 Aug 1;245:125443

Epitranscriptic regulation of HRAS by N(6)-methyladenosine drives tumor progression.

Pan Y, Gu Y, Liu T, Zhang Q, Yang F, Duan L, Cheng S, Zhu X, Xi Y, Chang X, Ye Q, Gao S
Proceedings of the National Academy of Sciences of the United States of America 2023 Apr 4;120(14):e2302291120

ALG3 Promotes Peritoneal Metastasis of Ovarian Cancer through Increasing Interaction of α1,3-mannosylated uPAR and ADAM8.

Cui X, Pei X, Wang H, Feng P, Qin H, Liu S, Yan Q, Liu J
Cells 2022 Oct 6;11(19)

Identification of NRAS Downstream Genes with CRISPR Activation Screening.

Tatsumi A, Hirakochi H, Inoue S, Tanaka Y, Furuno H, Ikeda M, Ishibashi S, Taguchi T, Yamamoto K, Onishi I, Sachs Z, Largaespada DA, Kitagawa M, Kurata M
Biology 2022 Oct 23;11(11)

RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.

Sun J, Wu G, Pastor F, Rahman N, Wang WH, Zhang Z, Merle P, Hui L, Salvetti A, Durantel D, Yang D, Andrisani O
Gut 2022 May;71(5):991-1005

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.

Odeniyide P, Yohe ME, Pollard K, Vaseva AV, Calizo A, Zhang L, Rodriguez FJ, Gross JM, Allen AN, Wan X, Somwar R, Schreck KC, Kessler L, Wang J, Pratilas CA
Oncogene 2022 May;41(21):2973-2983

Artemisinin inhibits NRas palmitoylation by targeting the protein acyltransferase ZDHHC6.

Qiu N, Abegg D, Guidi M, Gilmore K, Seeberger PH, Adibekian A
Cell chemical biology 2022 Mar 17;29(3):530-537.e7

Argonaute 2 modulates EGFR-RAS signaling to promote mutant HRAS and NRAS-driven malignancies.

Siebenaler RF, Chugh S, Waninger JJ, Dommeti VL, Kenum C, Mody M, Gautam A, Patel N, Chu A, Bawa P, Hon J, Smith RD, Carlson H, Cao X, Tesmer JJG, Shankar S, Chinnaiyan AM
PNAS nexus 2022 Jul;1(3):pgac084

Hepatocyte growth factor derived from senescent cells attenuates cell competition-induced apical elimination of oncogenic cells.

Igarashi N, Miyata K, Loo TM, Chiba M, Hanyu A, Nishio M, Kawasaki H, Zheng H, Toyokuni S, Kon S, Moriyama K, Fujita Y, Takahashi A
Nature communications 2022 Jul 18;13(1):4157

Ionic Liquid-Based Extraction System for In-Depth Analysis of Membrane Protein Complexes.

Chu H, Zhao Q, Liu J, Yang K, Wang Y, Liu J, Zhang K, Zhao B, He H, Zheng Y, Zhong S, Liang Z, Zhang L, Zhang Y
Analytical chemistry 2022 Jan 18;94(2):758-767

ADAR1 downregulation by autophagy drives senescence independently of RNA editing by enhancing p16(INK4a) levels.

Hao X, Shiromoto Y, Sakurai M, Towers M, Zhang Q, Wu S, Havas A, Wang L, Berger S, Adams PD, Tian B, Nishikura K, Kossenkov AV, Liu P, Zhang R
Nature cell biology 2022 Aug;24(8):1202-1210

Comprehensive Analysis of the Tumor Microenvironment and Ferroptosis-Related Genes Predict Prognosis with Ovarian Cancer.

Li XX, Xiong L, Wen Y, Zhang ZJ
Frontiers in genetics 2021;12:774400

Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma.

Xia ZK, Wang W, Qiu JG, Shi XN, Li HJ, Chen R, Ke KB, Dong C, Zhu Y, Wu SG, Zhang RP, Meng ZR, Zhao H, Gu P, Leung KS, Wong MH, Liu XD, Zhou FM, Zhang JY, Yao YT, Wang SJ, Zhang CY, Qin YR, Lin MC, Jiang BH
Frontiers in pharmacology 2021;12:691769

Polymeric nanoparticle mediated inhibition of miR-21 with enhanced miR-124 expression for combinatorial glioblastoma therapy.

Liu Y, Zheng M, Jiao M, Yan C, Xu S, Du Q, Morsch M, Yin J, Shi B
Biomaterials 2021 Sep;276:121036

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.

Liu C, Lu H, Wang H, Loo A, Zhang X, Yang G, Kowal C, Delach S, Wang Y, Goldoni S, Hastings WD, Wong K, Gao H, Meyer MJ, Moody SE, LaMarche MJ, Engelman JA, Williams JA, Hammerman PS, Abrams TJ, Mohseni M, Caponigro G, Hao HX
Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Jan 1;27(1):342-354

Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System.

Röth S, Macartney TJ, Konopacka A, Chan KH, Zhou H, Queisser MA, Sapkota GP
Cell chemical biology 2020 Sep 17;27(9):1151-1163.e6

Immunohistochemical assessment of growth factor signaling molecules: MAPK, Akt, and STAT3 pathways in oral epithelial precursor lesions and squamous cell carcinoma.

Tashiro K, Oikawa M, Miki Y, Takahashi T, Kumamoto H
Odontology 2020 Jan;108(1):91-101

Enhanced anti-tumor effect of liposomal Fasudil on hepatocellular carcinoma in vitro and in vivo.

Zhao Y, Zhang Y, Vazirinejad Mehdiabad M, Zhou K, Chen Y, Li L, Guo J, Xu C
PloS one 2019;14(10):e0223232

KRAS regulation by small non-coding RNAs and SNARE proteins.

Che Y, Siprashvili Z, Kovalski JR, Jiang T, Wozniak G, Elcavage L, Khavari PA
Nature communications 2019 Nov 11;10(1):5118

Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.

Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, Hobbs GA, Tessier-Cloutier B, Gillette WK, Bagni R, Whiteley GR, Hartley JL, McCormick F, Cox AD, Houghton PJ, Huntsman DG, Philips MR, Der CJ
Science signaling 2017 Sep 26;10(498)

Genetic and epigenetic silencing of mircoRNA-506-3p enhances COTL1 oncogene expression to foster non-small lung cancer progression.

Guo S, Yang P, Jiang X, Li X, Wang Y, Zhang X, Sun B, Zhang Y, Jia Y
Oncotarget 2017 Jan 3;8(1):644-657

ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma.

Xu S, Wang H, Pan H, Shi Y, Li T, Ge S, Jia R, Zhang H, Fan X
Cancer letters 2016 Oct 10;381(1):41-8

Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells.

Liu W, Ning R, Chen RN, Huang XF, Dai QS, Hu JH, Wang YW, Wu LL, Xiong J, Hu G, Guo QL, Yang J, Wang H
Molecular carcinogenesis 2016 May;55(5):440-57

No comments: Submit comment

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: Jurkat cells were subjected to SDS PAGE followed by western blot with 10724-1-AP(NRAS antibody) at dilution of 1:500
Sample type: cell line

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: The NRAS antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human NRAS. This antibody recognizes human,mouse,rat antigen. The NRAS antibody has been validated for the following applications: ELISA, WB, IF, IHC analysis.
Appendix: 10724-1-AP.pdf

: Show more

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: Immunohistochemical of paraffin-embedded human testis using 10724-1-AP(NRAS antibody) at dilution of 1:50 (under 10x lens)
Sample type: tissue

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: Immunohistochemical of paraffin-embedded human testis using 10724-1-AP(NRAS antibody) at dilution of 1:50 (under 40x lens)
Sample type: tissue